Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Non-Hodgkin Lymphoma
About this trial
This is an interventional treatment trial for Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Eligibility Criteria
Criteria: Platelet count at least 100,000/mm^3 No leukemia No active CNS involvement with tumor ECOG 0-2 Life expectancy: at least 3 months Absolute neutrophil count at least 2,000/mm^3 No New York Heart Association class III or IV heart failure No history of myocardial infarction within the past year Bilirubin =< upper limit of normal (ULN) AST no greater than 2 times ULN (no greater than 98 U/L) No uncontrolled dysrhythmias No poorly controlled angina No serious ventricular arrhythmia (i.e., ventricular tachycardia (VT) or ventricular fibrillation (VF) >= 3 beats in a row) QTc interval =< 450 msec for men or =< 470 msec for women LVEF >= 40% by MUGA Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception HIV negative No other serious medical condition that would preclude study participation No serious hypersensitivity to egg products No concurrent anticancer immunotherapy At least 4 weeks since prior chemotherapy and recovered No other concurrent anticancer chemotherapy (e.g., cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] or mechlorethamine, vincristine, procarbazine, and prednisone [MOPP]) No concurrent anticancer hormonal therapy Concurrent glucocorticoids as antiemetics for nonmalignant disease allowed At least 4 weeks since prior radiotherapy and recovered No concurrent radiotherapy No concurrent major surgery No concurrent anticancer glucocorticoids Creatinine =< ULN or Creatinine clearance at least 60 mL/min No concurrent medications that cause QTc prolongation Histologically confirmed advanced solid tumor for which no curative therapy exists Non-Hodgkin's lymphoma allowed No concurrent drugs that interfere with hepatic CYP3A4 metabolism (e.g., grapefruit juice, ketoconazole, fluconazole, itraconazole, cyclosporine, erythromycin, clarithromycin, cimetidine, terfenadine, astemizole, indinavir, or nelfinavir mesylate)
Sites / Locations
- University of Nebraska Medical Center
Arms of the Study
Arm 1
Experimental
Treatment (tanespimycin)
Patients will receive infusions of tanespimycin analogue twice a week in weeks 1 and 3.